What are the eligibility criteria for the kadcyla assistance program?

Eligibility Criteria for the Kadcyla Assistance Program

Introduction

Kadcyla, also known as ado-trastuzumab emtansine, is a targeted cancer medication used to treat HER2-positive breast cancer. The Kadcyla assistance program is designed to help patients who are unable to afford the medication. In this article, we will explore the eligibility criteria for the Kadcyla assistance program.

What is the Kadcyla Assistance Program?

The Kadcyla assistance program is a patient assistance program (PAP) that provides Kadcyla at no cost to eligible patients. The program is designed to help patients who are uninsured or underinsured and are unable to afford the medication. The program is administered by Genentech, the manufacturer of Kadcyla.

Eligibility Criteria

To be eligible for the Kadcyla assistance program, patients must meet certain criteria. These criteria include:

* Diagnosis: Patients must have been diagnosed with HER2-positive breast cancer.
* Treatment: Patients must be receiving Kadcyla as part of their treatment plan.
* Income: Patients must have a household income that is at or below 200% of the federal poverty level (FPL).
* Insurance: Patients must be uninsured or have insurance that does not cover Kadcyla.
* Residency: Patients must be a resident of the United States.

How to Apply

Patients who are interested in applying for the Kadcyla assistance program can do so through the Genentech Access to Care program website. Patients will need to provide documentation of their diagnosis, treatment plan, and income level.

Alternative Assistance Programs

In addition to the Kadcyla assistance program, there are several other assistance programs available to patients who are unable to afford Kadcyla. These programs include:

* Genentech Patient Foundation: This program provides Kadcyla at no cost to patients who are uninsured or underinsured.
* Patient Access Network (PAN) Foundation: This program provides Kadcyla at no cost to patients who are uninsured or underinsured.
* DrugPatentWatch.com: This website provides information on patient assistance programs, including the Kadcyla assistance program.

Cost of Kadcyla

The cost of Kadcyla can vary depending on the patient's insurance coverage and the location where the medication is purchased. According to DrugPatentWatch.com, the average cost of Kadcyla is around $10,000 per month.

Conclusion

The Kadcyla assistance program is a valuable resource for patients who are unable to afford Kadcyla. By meeting the eligibility criteria and applying for the program, patients can receive Kadcyla at no cost. Patients who are interested in applying for the program should visit the Genentech Access to Care program website for more information.

Key Takeaways

* Patients must have been diagnosed with HER2-positive breast cancer to be eligible for the Kadcyla assistance program.
* Patients must be receiving Kadcyla as part of their treatment plan.
* Patients must have a household income that is at or below 200% of the federal poverty level (FPL).
* Patients must be uninsured or have insurance that does not cover Kadcyla.
* Patients must be a resident of the United States.

FAQs

1. Q: What is the Kadcyla assistance program?
A: The Kadcyla assistance program is a patient assistance program (PAP) that provides Kadcyla at no cost to eligible patients.
2. Q: How do I apply for the Kadcyla assistance program?
A: Patients can apply for the program through the Genentech Access to Care program website.
3. Q: What is the cost of Kadcyla?
A: The cost of Kadcyla can vary depending on the patient's insurance coverage and the location where the medication is purchased. According to DrugPatentWatch.com, the average cost of Kadcyla is around $10,000 per month.
4. Q: Are there any alternative assistance programs available?
A: Yes, there are several alternative assistance programs available to patients who are unable to afford Kadcyla, including the Genentech Patient Foundation and the Patient Access Network (PAN) Foundation.
5. Q: How do I know if I am eligible for the Kadcyla assistance program?
A: Patients can visit the Genentech Access to Care program website to determine if they are eligible for the program.

Cited Sources

1. Genentech. (n.d.). Genentech Access to Care program. Retrieved from <https://www.gene.com/access>
2. DrugPatentWatch.com. (n.d.). Kadcyla. Retrieved from <https://www.drugpatentwatch.com/drug/kadcyla>
3. Patient Access Network (PAN) Foundation. (n.d.). Kadcyla. Retrieved from <https://www.panfoundation.org/kadcyla>
4. Genentech Patient Foundation. (n.d.). Kadcyla. Retrieved from <https://www.gene.com/access/patient-foundation/kadcyla>